DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA553566
Title:
Rosiglitazone and Fenofibrate Additive Effects on Lipids
Descriptive Note:
Journal article
Corporate Author:
BROOKE ARMY MEDICAL CENTER FORT SAM HOUSTON TX
Report Date:
2011-10-01
Pagination or Media Count:
5.0
Abstract:
To evaluate the effect of rosiglitazone, fenofibrate, or their combined use on plasma lipids in normoglycemic healthy adults.Methods and Results. Subjects were randomized in a double-blind fashion to rosiglitazone placebo, fenofibrate placebo, rosiglitazone fenofibrate, or matching double placebo. The between-group difference in the change in fasting TG, high-density lipoprotein cholesterol HDL-C, LDL-C, and plasma apolipoproteins A-I, A-II, and C-III level were compared after 12 weeks of treatment. A total of 548 subjects were screened and 41 met the inclusion criteria. After 12 weeks of therapy, the median change in the triglyceride levels showed a significant reduction ranging from 47 to 55 mg per deciliter in the fenofibrate only and rosiglitazone fenofibrate groups compared with placebo P 0.0496. However, the rosiglitazone only group did not show significant change in triglyceride level. The change in the Apo AII showed increase in all the treatment groups compared with placebo P 0.009. There was also significant change in the Apo CIII that showed reduction of its level in the fenofibrate only and rosiglitazone fenofibrate groups P 0.0003. Conclusion. Rosiglitazone does not appear to modulate hypertriglyceridemia in patients with elevated triglycerides independent of glucose metabolism.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE